Passage Bio Inc - ESG Rating & Company Profile powered by AI
This page is a free Sustainability assessment for Passage Bio Inc. Full ESG assessment of Passage Bio Inc can be reached by signing in. If you work at Passage Bio Inc and you wish to use your Sustainability aseessment, please contact us.
Passage Bio Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 3.4; made up of an environmental score of 1.6, social score of 3.2 and governance score of 5.3.
3.4
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| ... | ... | ... | |
| 1617 | VistaGen Therapeutics Inc | 3.5 | Medium |
| 1617 | Yumanity Therapeutics Inc | 3.5 | Medium |
| 1659 | Passage Bio Inc | 3.4 | Medium |
| 1659 | Acceleron Pharma Inc | 3.4 | Medium |
| 1659 | Annexin Pharmaceuticals AB (publ) | 3.4 | Medium |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Passage Bio Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Passage Bio Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Passage Bio Inc report the average age of the workforce?
Sign up for free to unlockDoes Passage Bio Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Passage Bio Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Passage Bio Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Passage Bio Inc offer flexible work?
Sign up for free to unlockDoes Passage Bio Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Passage Bio Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Passage Bio Inc conduct supply chain audits?
Sign up for free to unlockDoes Passage Bio Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Passage Bio Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Passage Bio Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Passage Bio Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Passage Bio Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Passage Bio Inc disclose water use targets?
Sign up for free to unlockDoes Passage Bio Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Passage Bio Inc have a product recall in the last two years?
Sign up for free to unlockDoes Passage Bio Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Passage Bio Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Passage Bio Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Passage Bio Inc disclose parental leave metrics?
Sign up for free to unlockDoes Passage Bio Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Passage Bio Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Passage Bio Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Passage Bio Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Passage Bio Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Passage Bio Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Passage Bio Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Passage Bio Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Passage Bio Inc disclose its waste policy?
Sign up for free to unlockDoes Passage Bio Inc report according to TCFD requirements?
Sign up for free to unlockDoes Passage Bio Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Passage Bio Inc disclose energy use targets?
Sign up for free to unlockDoes Passage Bio Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Passage Bio Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Passage Bio Inc
These potential risks are based on the size, segment and geographies of the company.
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and PBCM06 for the treatment of Charcot-Marie-Tooth Type 2A. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.